<DOC>
	<DOCNO>NCT02300883</DOCNO>
	<brief_summary>This observational prospective analysis biological characteristic malignant mesothelioma ( MM ) patient . Frozen paraffin-embedded tumor specimens pleural effusion patient collect analyzed follow analysis : 1Purification Tumour Associated Macrophages ( TAM ) tumour cell pleural effusion . 2.Mass spectrometry analysis TAMs tumor cell 3.Co focal microscopy analysis macrophage , tumour cell specimen derive patient .</brief_summary>
	<brief_title>Observational Prospective Analysis Biological Characteristics Mesothelioma Patients</brief_title>
	<detailed_description>This observational prospective analysis biological characteristic malignant pleural mesothelioma ( MPM ) patient . Frozen paraffin-embedded tumor specimens pleural effusion patient collect analyzed follow analysis : 1 . Purification TAMs tumour cell pleural effusion . Pleural effusion subject centrifugation order separate cellular non-cellular component . Cell-free supernatant collect subjected analysis identification characterization secrete protein ( ELISA , Western Blot ) . Pleural effusion cell component characterize cytofluorimetry order evaluate leukocytes composition ( e.g . macrophage , neutrophil , lymphocyte ) . Next , isolate TAMs cellular component , investigator adopt standard protocol currently perform investigator group purify TAMs ascites derive ovarian carcinoma patient . Briefly , TAMs separate selective capacity adhere culture plat serum-free condition . After 1 hour incubation , non-adherent cell ( mainly tumour cell inflammatory cell ) thoroughly wash jet medium . After adherence , cell rest 1 hour standard culture condition subsequently lysed extract protein . To isolate tumour cell leukocytes , cell sorting-based approach use . Briefly , inflammatory cell stain lymphocyte common antigen ( CD45 ) antibody negative cell ( tumour cell ) separate cell sort . Next tumour cell grow amplified standard culture condition . 2 . Mass spectrometry analysis TAMs tumor cell Generation proteome phospho-proteomic map TAMs tumour cell accomplish quantitation entire proteome phospho-proteome . Results obtain TAMs compare untreated , M1 M2 polarize Monocytes-derived macrophage ( M-DM ) , tumor cell purify patient ' pleural effusion analyse respect human mesothelial cell . Protein sample obtain purified TAMs tumour cell , derive patient 's pleural effusion , extract use lysis/acetone precipitation . Cell extract subsequently subject trypsin digestion result peptide label `` iTRAQ '' reagent . Labelled peptide separate first dimension separation strong cation exchange ( SCX ) chromatography . Fractions collect phospho-enriched , require . The pooled mixture peptide submit second dimension chromatographic separation , organize two-step process : desalting/concentrating pre-column , analytical column separation . System nano-flow configuration , direct interfacing mass spectrometer . Tandem mass spectrometry perform hybrid ion-trap ( IT ) - Fourier transform ion-cyclotron-resonance mass spectrometer . Quantitative identification data analysis carry Proteome Discoverer software ( Thermo ) , use SEQUEST search engine . Statistical analysis data classification carry aid in-house write script freeware statistical analysis package . 3 . Co focal microscopy analysis macrophage , tumour cell specimen derive patient . The analysis conduct cellular component derive pleural effusion ( previously describe ) frozen paraffin-embedded tissue . Immunofluorescence stain perform marker DNA damage polarize inflammation . Furthermore , immunofluorescence analysis hold validate putative new MM molecular marker obtain mass spectrometry study .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<criteria>Malignant pleural mesothelioma patient Availability plural effusion frozen paraffinembedded tumor specimen . Unavailability plural effusion frozen paraffinembedded tumor specimen .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>